表1 纳入研究的基本情况
(n)
纳入研究 |
菌株来源 |
样本量 | ||
RFP敏感株 | RFP耐药株 | |||
刘敬华,张丽水,刘志广,等.中华流行病学杂志,2006,27(11). | 福建 | 37 | 47 | |
李苗,司红艳,郭璐,等.中华结核和呼吸杂志, 2010,33(2). | 甘肃 | 2 | 17 | |
Tan Y, Hu Z, Zhao Y,et al.J Clin Microbiol. 2012,50(1). | 广东、广西、湖南、江西、海南 | 30 | 362 | |
Yuan X, Zhang T, Kawakami K,et al.J Clin Microbiol. 2012,50(7). | 江西 | 20 | 77 | |
Tang K, Sun H, Zhao Y,et al.Tuberculosis(Edinb). 2013,93(1). | 四川 | 55 | 214 | |
Zhao LL, Chen Y, Liu HC,et al.Antimicrob Agents Chemother. 2014,58(4). |
福建、贵州、广西、山西、上海、西藏 | 0 | 128 | |
Guo Q, Yu Y, Zhu YL,et al.Biomed Environ Sci. 2015,28(1). | 西藏、湖南、新疆、河南、四川、安徽 | 119 | 87 |
表2 932株利福平耐药中国MTB株rpoB基因非RRDR序列基因突变情况
突变位点 | AA变化 | n | % | 突变位点 | AA变化 | n | % | 突变位点 | AA变化 | n | % |
146 | V/F | 4 | 0.43 | 491,526 | T/Q,H/D | 1 | 0.11 | 531,272 | S/L,K/E | 1 | 0.11 |
176 | V/F | 2 | 0.21 | 511,572 | L/P,I/M | 1 | 0.11 | 531,335 | S/L,S/P | 1 | 0.11 |
206 | P/R | 1 | 0.11 | 511,572 | L/P,I/F | 1 | 0.11 | 531,367 | S/L,A/V | 1 | 0.11 |
314 | Y/C | 2 | 0.21 | 511,574 | L/P,S/L | 3 | 0.32 | 531,386 | S/L,V/L | 2 | 0.21 |
323 | H/Y | 1 | 0.11 | 511,574 | L/P,S/F | 3 | 0.32 | 531,480 | S/L,T/I | 1 | 0.11 |
505 | F/F | 1 | 0.11 | 513,247 | Q/L,E/G | 1 | 0.11 | 531,481 | S/L,T/A | 2 | 0.21 |
572 | I/F | 1 | 0.11 | 513,561 | Q/E,I/V | 1 | 0.11 | 531,561 | S/L,I/T | 2 | 0.21 |
572 | I/T | 1 | 0.11 | 513,564 | Q/P,P/S | 1 | 0.11 | 531,569 | S/L,I/V | 1 | 0.11 |
626 | D/E | 1 | 0.11 | 513,574 | Q/K,S/P | 1 | 0.11 | 531,572 | S/L,I/V | 4 | 0.43 |
657 | P/H | 1 | 0.11 | 513,633 | Q/P,R/L | 1 | 0.11 | 531,577 | S/L,V/G | 1 | 0.11 |
657 | P/P | 1 | 0.11 | 513,880 | Q/K,Q/K | 1 | 0.11 | 531,584 | S/L,F/S | 4 | 0.43 |
891 | K/T | 1 | 0.11 | 513,916 | Q/K,H/R | 1 | 0.11 | 531,603 | S/L,I/M | 2 | 0.21 |
144,526 | V/G,H/N | 1 | 0.11 | 516,253 | D/Y,Q/R | 1 | 0.11 | 531,615 | S/L,V/M | 1 | 0.11 |
146,402 | V/F,P/S | 1 | 0.11 | 516,541 | Q缺失,E/G | 1 | 0.11 | 531,621 | S/L,S/A | 1 | 0.11 |
149,516 | L/P,D/G | 1 | 0.11 | 516,572 | D/G,I/L | 1 | 0.11 | 531,626 | S/L,D/E | 1 | 0.11 |
195,531 | R/G,S/L | 1 | 0.11 | 516,572 | D/Y,I/M | 2 | 0.21 | 531,643 | S/L,V/M | 1 | 0.11 |
261,251 | H/D,D/V | 1 | 0.11 | 516,572 | D/E,I/T | 1 | 0.11 | 531,652 | S/L,D/G | 1 | 0.11 |
311,060 | S/L,L/R | 1 | 0.11 | 516,572 | D/Y,I/L | 1 | 0.11 | 531,655 | S/L,D/E | 1 | 0.11 |
311,112 | S/L,V/A | 1 | 0.11 | 526,459 | H/Y,L/R | 1 | 0.11 | 533,346 | L/P,D/G | 2 | 0.21 |
381,531 | A/V,S/L | 1 | 0.11 | 526,541 | H/Y,E/G | 4 | 0.43 | 533,562 | L/P,E/A | 2 | 0.21 |
457,531 | G/V,S/L | 1 | 0.11 | 526,572 | H/S,I/L | 1 | 0.11 | 139,201,167 | Q/K,G/C,K/R | 1 | 0.11 |
459,526 | L/R,H/Y | 1 | 0.11 | 526,572 | H/N,I/L | 1 | 0.11 | 490,516,526 | Q/H,D/Y,H/D | 1 | 0.11 |
472,526 | D/G,H/Y | 1 | 0.11 | 526,574 | H/N,S/T | 1 | 0.11 | 511,572,643 | L/P,I/L,E/G | 1 | 0.11 |
472,531 | E/Q,S/L | 1 | 0.11 | 526,626 | H/R,D/E | 1 | 0.11 | 515,526,535 | M/V,H/H,P/S | 1 | 0.11 |
481,526 | T/T,H/Y | 2 | 0.21 | 526,952 | H/R,R/H | 1 | 0.11 | 526,511,420 | H/Q,L/P,L/V | 1 | 0.11 |
481,531 | T/T,S/L | 1 | 0.11 | 531,103 | S/L,S/L | 1 | 0.11 | 531,345,955 | S/W,S/P,S/Y | 1 | 0.11 |
481,531 | T/A,S/L | 2 | 0.21 | 531,111 | S/L,P/S | 1 | 0.11 | 531,615,626 | S/L,V/M,D/E | 1 | 0.11 |
490,531 | Q/H,S/L | 1 | 0.11 | 531,126 | S/L,P/A | 1 | 0.11 | 490-491/415-416 | H/N,P/L | 1 | 0.11 |
491,526 | T/R,H/R | 1 | 0.11 | 531,126 | S/L,P/S | 3 | 0.32 | 插入C,526,535 |
参考文献
[1] GOLDSTEIN B P. Resistance to rifampicin: a review [J]. J Antibiot(Tokyo), 2014,67(9):625-630.
[2] AHMAD S, MOKADDAS E, FARES E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai [J]. Diagn Microbiol Infect Dis, 2002,44(3):245-252.
[3] CHEN L, GAN X, LI N,et al. rpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Guizhou, one of the highest incidence rate regions in China[J]. J Antimicrob Chemother, 2010,65(6):1299-1301.
[4] SIU G K, ZHANG Y, LAU T C, et al. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2011,66(4):730-733.
[5] TAN Y, HU Z, ZHAO Y, et al. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China[J]. J Clin Microbiol, 2012,50(1):81-85.
[6] ESPINAL MA, DYE C, RAVIGLIONE M, et al. Rational 'DOTS plus' for the control of MDR-TB[J]. Int J Tuberc Lung Dis, 1999,3(7):561-563.
[7] 吴雪琼,张宗德,乐军.分枝杆菌分子生物学[M].北京:人民军医出版社,2010:125-139.
[8] HILLEMANN D, R?SCH-GERDES S, RICHTER E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens[J]. J Clin Microbiol, 2007,45(8):2635-2640.
[9] GUO Y, ZHOU Y, WANG C, et al. Rapid, accurate determination of multidrug resistance in M. tuberculosis isolates and sputum using a biochip system[J]. Int J Tuberc Lung Dis, 2009,13(7):914-920.
[10] 卓文基,刘志辉,钱明,等.一线抗菌素结核药物不同耐药表型的利福平耐药结核杆菌rpoB基因突变分析[J].现代医院,2014,14(4):4-6.
[11] SIU G K, ZHANG Y, LAU T C, et al. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2011,66(4):730-733.
[12] JAMIESON F B, GUTHRIE J L, NEEMUCHWALA A, et al. Profiling of rpoB Mutations and MICs for Rifampin and Rifabutin in Mycobacterium tuberculosis[J]. J Clin Microbiol, 2014,52(6):2157-2162.
① 本网版权均属于现代医院杂志社,转载、摘编应在授权范围内使用,应注明"来源出处:《现代医院》杂志社"。违者本网将追究相关法律责任。
② 如有疑问和问题请联系现代医院杂志社服务热线:020-83310901 83310902
2020年,每个人心中都可能萦绕着一个问题 疫情之后,是爆发报复性反弹?还是缓慢有......
广东省医院各学科恢复不平衡,但总体向好 。 疫情在国内虽然被控制了,但不少医院......